F. Hoffmann-La Roche Ltd: Roche presents new and updated data for Polivy in previously untreated diffuse large B-cell lymphoma at ASH 2022

Updated data from the phase III POLARIX study continue to demonstrate a statistically significant reduction in the risk of disease worsening or death for people with previously untreated diffuse large

Related Keywords

Lugano ,Ticino ,Switzerland ,Japan ,United States ,Canada ,America ,American ,Levi Garraway ,Mabthera Rituxan ,Gazyva Gazyvaro ,Sabine Borngr ,Gerard Tobin ,Bruno Eschli ,Venclexta Venclyxto ,Birgit Masjost ,Loren Kalm ,Nathalie Altermatt ,American Society Of Hematology ,Genentech ,Drug Administration ,Roche Group ,Head Of Global Product Development ,Roche Group Media Relations ,American Society ,Annual Meeting ,Chief Medical Officer ,Global Product ,Biologics License Application ,Lugano Response Criteria ,Dow Jones Sustainability Indices ,Chugai Pharmaceutical ,Previously Untreated Diffuse Largeb Cell ,Hoffmann ,Oche ,Presents ,Pdated ,Data ,Polivy ,Reviously ,Untreated ,Diffuse ,Barge ,Fell ,Lymphoma ,022 ,